About

The BREATHE Initiative

Asthma is a chronic inflammatory disease of the airways characterized by recurrent episodes of wheezing, cough, chest tightness, and/or shortness of breath, usually accompanied by widespread but variable airflow obstruction. Asthma is a growing concern in this country. Roughly 20 million adults and approximately 6.2 million children in the US have asthma.

While diagnostic and management models of asthma continue to evolve, there are still a number of barriers to effective treatment and gaps in knowledge and performance that practitioners must overcome in order to advance positive patient outcomes. Many of these gaps involve treating challenging patients, ensuring adherence to medications, and tailoring the therapy to the patient based on characteristics determined by the interaction of both genes and environment.

There is an ongoing medical need for the improved management of those patients with uncontrolled, moderate-to-severe asthma. The developing pathophysiologic model of severe asthma has identified specific molecular pathways, moving the concept of clinical phenotypes toward that of molecular phenotypes, resulting in the integration of molecularly targeted biological agents into patient care. An understanding of the underlying, inflammatory processes and targeted therapeutic agents is integral to the clinicians’ understanding of the heterogeneity of moderate-to-severe asthma.

Our Asthma BREATHE site serves to provide information on asthma that supports the personalization of care and helps narrow the difficulty of navigating though the dynamic field of personalizing asthma treatment.